Diamonds and Dogs


The diamond of the day goes to Viking Therapeutics jumping 118% thanks to positive top line results for their obesity drug. Viking's phase 2 results showed patients in a mid-stage trail lost 14% of their body weight after just 13 weeks. The drug trial was not big, but investors are speculating Viking's drug could rival Eli Lilly's weight loss drug, Zepbound.

A second diamond today, Norwegian Cruise Line (NCLH) is jumping 19% following earnings and good guidance as the cruise line is carrying more cruisers now than ever (higher capacity), with full occupancy, average ticket prices higher and onboard spending up as well.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.